The effect of retreatment with interferon-α on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C
✍ Scribed by Hidenori Toyoda; Takashi Kumada; Satoshi Nakano; Isao Takeda; Keiichi Sugiyama; Seiki Kiriyama; Yasuhiro Sone; Yasuhiro Hisanaga
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 86 KB
- Volume
- 88
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
BACKGROUND. Interferon (IFN) has been reported to have beneficial long term effects that reduce the occurrence of hepatocellular carcinoma (HCC), even in patients who do not have complete responses to IFN. The authors evaluated the effect of retreatment with IFN-␣ on the long term prognoses of those with incomplete responses to their initial IFN-␣ treatment.
METHODS.
Among 271 patients with incomplete responses to initial IFN-␣ treatment who had received sufficient dose and duration (a total dose of more than 350 megaunits administered over a period longer than 12 weeks) between October 1989 and September 1997, 63 patients received retreatment and 208 did not. The authors retrospectively compared the incidence of HCC between patients who received retreatment and those who did not.
RESULTS.
There were no significant differences in the clinical characteristics between these two groups. The cumulative incidence of HCC was significantly lower among the patients who had retreatment, and retreatment with IFN-␣ was the only factor that correlated with the lower incidence of HCC in multivariate analysis. The results were similar when the 12 patients with complete responses to retreatment were excluded from the analysis.
📜 SIMILAR VOLUMES
## BACKGROUND. To determine whether interferon (IFN) therapy can reduce incidence of the development of cirrhosis and hepatocellular carcinoma equally in patients with chronic hepatitis C virus (HCV) who responded differently to therapy, a retrospective analysis of 250 patients treated with IFN wa
## BACKGROUND. Recently, it has been reported that hepatitis B virus (HBV) DNA is detected in cancerous liver tissues in some hepatitis B surface antigen negative chronic hepatitis C patients with hepatocellular carcinoma (HCC). However, the significance of HBV DNA detected in such cases remains u
Of 74 patients who were infected with hepatitis C virus (HCV) and received interferon, 12 (16%) were positive for RNA of GB virus C (GBV-C). RNA of GBV-C was determined in sera from the co-infected patients retrospectively, and the effect of interferon on GBV-C was compared with that on HCV in them.
To evaluate the role of hepatitis C virus (HCV) in Chinese patients with hepatocellular carcinoma (HCC), the antibodies to HCV (anti-HCV) were detected by enzyme immunoassay in 41 (12.6%) of the 326 patients with HCC. However, none of 35 patients with metastatic carcinoma of the liver had detectable
The authors thank Dr. Adrian M. Di Bisceglie for helpful suggestions and discussions and also for providing the plasmid-containing, full-length HBV-DNA.